Vaxcyte's VAX-31 Phase 3 Trials Fully Enrolled, Topline Data Set for Q4 2026
PCVX sits 100% above its 52-week low of $29.08.
Summary
Vaxcyte has fully enrolled all three Phase 3 adult trials for its pneumococcal vaccine candidate VAX-31, a critical milestone that de-risks the program's timeline. The company now guides for OPUS-1 topline data in Q4 2026, with OPUS-2 and OPUS-3 results following in the first half of 2027. With $2.5 billion in cash, Vaxcyte is well-funded through these readouts and potential milestones, addressing a key investor concern about dilution risk. The stock has underperformed recently, down 5.9% last quarter, but analysts see significant upside with a median $110 target—roughly double the last close. This enrollment update, combined with the specific data catalysts, provides a clear near-term value driver that traders can position around.
At the time of this announcement, PCVX was trading at $58.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6B. The 52-week trading range was $29.08 to $65.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.